UK Will Pay for Roche Breast Cancer Drug at Centre of Price Row
LONDON — A Roche breast cancer drug at the centre of a prolonged pricing row in Britain will now be paid for routinely, following a discount deal between the company and the National Health Service (NHS). The National Institute for Health and Care Excellence (NICE) said on Thursday it could now recommend funding for Kadcyla, following the new commercial access arrangement with Roche. Kadcyla, which can prolong the lives of some women with advanced disease, has been a battle-ground for campaigners wanting better access to modern cancer drugs, with 115,000 people signing a petition demanding its availability. Details of the discount offer were not disclosed. "Today's announcement on Kadcyla shows that for companies who are willing to work with us, there are concrete gains for them, for the NHS and most importantly for patients able to get new and innovative drugs," said NHS England chief Simon Stevens.
This Woman's Chest 'Freckles' Were a Rare Sign of Breast Cancer
The cancer moves quickly, often in a matter of weeks or months and, compared with other types of breast cancer, inflammatory breast cancer tends to be diagnosed at younger ages. This symptom is so rare that some doctors have never heard of inflammatory breast cancer showing up this way. With that said, it's hard to overstate how uncommon this is as a sign of inflammatory breast cancer. Overall, experts want you to know that inflammatory breast cancer is rare, and the freckle symptom is especially rare. The skin changes show up because inflammatory breast cancer clogs the lymphatic vessels that drain fluid from the breast, Dr. Woodward explains.collected by :Lucy William
No comments:
Post a Comment